Start-up raises hope in the fight against acute and chronic liver diseases
The biotech company HepaRegeniX, founded in 2017, starts clinical testing of the tolerability of its developed drug in volunteers.
11-Aug-2021 -
The Tübingen-based start-up HepaRegeniX recently began a Phase I clinical trial to test the tolerability of a novel drug against liver disease in healthy volunteers. The drug is a so-called MKK4 inhibitor, which, when administered, curbs the activity of the kinase MKK4. Preclinical studies have ...
drug development
liver diseases
